Skip to main content

Advertisement

SpringerLink
Log in

Gerontology Forum

An Update on the Literature

  • From the World Literature
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Notes

  1. This study was supported by a grant from Allergan Inc., US, with which the researchers were affiliated.

  2. The study was conducted from a healthcare payers’ perspective. Costs (year 2003 values) were those associated with study medications, adjunctive medications and physician visits.

  3. One of the authors was affiliated with Eli Lilly Inc., Merck & Co., and Aventis.

  4. Sponsored by Sanofi-Aventis.

  5. Costs (2004 values) were reported from a US payer perspective and were those related to treatments and complications. Costs and benefits were discounted by 3% per annum.

  6. Nymox Pharmaceutical Corporation, phase II for benign prostatic hyperplasia in the US.

  7. Preceded by 2-week antihypertensive washout period.

  8. Targacept, R.J. Reynolds Tobacco Company; phase II for cognition disorders in the US.

  9. One of the authors had affiliations with Bristol-Myers Squibb and AstraZeneca.

  10. Congestive heart failure, Hypertension, Age, Diabetes, Stroke.

  11. Hepatic or renal disease, Ethanol abuse, Malignancy, Older age (>75 years), Reduced platelet count or function, Hypertension (uncontrolled), Anaemia, Genetic factors, Excessive fall risk, Stroke.

  12. This study was supported by Eisai and Pfizer.

  13. Patients randomised to the donepezil 10 mg/day group received donepezil 5 mg/day for the first 6 weeks of the study.

  14. This study was supported by Pfizer.

  15. Patients randomised to the donepezil 10 mg/day group received donepezil 5 mg/day for the first 30 days of the study.

  16. This study was supported by GlaxoSmithKline.

  17. Dosage increases were permitted after every 7 days up to a dosage of 2 mg/day, and every 14 days for dosages beyond this.

  18. This study was funded by Pfizer, US, and Eisai, US.

  19. This study was funded by Pfizer Pharmaceuticals, Sweden.

  20. Voyager Pharmaceuticals; phase III for Alzheimer’s disease in Canada and the US.

  21. The testosterone and placebo gels were supplied by Unimed Pharmaceuticals Inc.

  22. The Judgment of Line Orientation, the Developmental Test of Visual-Motor Integration, and the Block Design Subtest of the Wechsler Adult Intelligence Scale-revised.

  23. Costs (2002 values) were long-term care, inpatient and outpatient care, home healthcare, short-term facility and hospice care, and prescribed medication costs.

  24. This study was sponsored by Eli Lilly.

  25. The authors were affiliated with Lundbeck A/S, France.

  26. This study was supported by Novartis Pharma, Switzerland.

  27. ACADIA Pharmaceuticals; phase II for psychotic disorders and movement disorders in the US.

Reference

  • University of Michigan. More than half of older diabetics lack medicines that protect kidneys and heart, U-M study finds [media release]. 18 Apr 2006. University of Michigan [online]. Available from URL: http://www.med.umich.edu [Accessed 2006 May 20]

    Google Scholar 

Reference

  • Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. PharmacoEconomics 2006; 24(3): 251–64

    Article  PubMed  CAS  Google Scholar 

Reference

  • Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 Feb; 99(2): 123–31

    Article  PubMed  Google Scholar 

Reference

  • Cook IF, Barr I, Hartel G, et al. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2006; 24(13): 2395–402

    Article  PubMed  CAS  Google Scholar 

Reference

  • Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97(4): 734–41

    Article  PubMed  CAS  Google Scholar 

Reference

  • DiSantostefano RL, Biddle AK, Lavelle JP. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. PharmacoEconomics 2006; 24(2): 171–91

    Article  PubMed  Google Scholar 

Reference

  • Nishino Y, Masue T, Miwa K, et al. Comparison of two alpha-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006; 97(4): 747–51

    Article  PubMed  CAS  Google Scholar 

Reference

  • Nymox reports positive new efficacy data for benign prostatic hyperplasia drug [media release]. 16 May 2006. Hasbrouck Heights (NJ): Nymox Pharmaceutical Corporation [online]. Available from URL: http://www.nymox.com [Accessed 2006 May 27]

Reference

  • Malaguarnera M, Di Mauro A, Gargante PM, et al. L-carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. South Med J 2006; 99(3): 315–6

    Article  PubMed  Google Scholar 

Reference

  • Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006; 20(3): 177–85

    Article  PubMed  CAS  Google Scholar 

Reference

  • Targacept announces positive phase II results for TC-1734 (AZD3480) in memory impaired older subjects [media release]. 17 May 2006. Targacept Inc. [online]. Available from URL: http://www.targacept.com [Accessed 2006 May 27]

References

  1. Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006 Apr; 37(4): 1075–80

    Article  PubMed  Google Scholar 

  2. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006 Apr; 37(4): 1070–4

    Article  PubMed  CAS  Google Scholar 

References

  1. Black S, Li H, McRae T, et al. Treatment of severe Alzheimer’s disease with donepezil: results from a 24-week, multinational, randomized, double-blind, placebo-controlled trial [abstract no. P06.057 plus poster]. Neurology 2006 Mar 14; 66 (5 Suppl. 2): 347

    Google Scholar 

  2. Winblad B, Eriksson S, Kilander L, et al. Efficacy of donepezil on secondary end points in a randomized, double-blind, placebo-controlled study in severe Alzheimer’s disease [abstract no. PO6.069 plus poster]. Neurology 2006 Mar 14; 66 (5 Suppl. 2): 350

    Google Scholar 

Reference

  1. Kushida CA, Tolson JM. Ropinirole is an effective treatment for patients with restless legs syndrome needing extended treatment coverage [abstract no. PO2.029 plus poster]. Neurology 2006 Mar 14; 66 (5 Suppl. 2): 82

    Google Scholar 

Reference

  • Johannsen P, Salmon E, Hampel H, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease. CNS Drugs 2006; 20(4): 311–25

    Article  PubMed  CAS  Google Scholar 

Reference

  • Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006 Apr 1; 367(9516): 1057–65

    Article  PubMed  CAS  Google Scholar 

Reference

  • Leuprolide acetate stabilizes cognitive and functional decline in women with Alzheimer’s disease, study shows [media release]. 16 May 2006. Voyager Pharmaceutical Corporation [online]. Available from URL: http://www.voyagerpharma.com [Accessed 2006 May 27]

Reference

  • Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006; 63(2): 177–85

    Article  PubMed  Google Scholar 

Reference

  • New guidelines improve diagnosis for people with Parkinson disease [media release]. 28 Mar 2006. American Academy of Neurology [online]. Available from URL: http://www.aan.com [Accessed 2006 Apr 29]

References

  1. American Academy of Neurology. Compulsive behaviors are common from Parkinson treatment [media release]. 24 Mar 2006. Newswire [online]. Available from URL: http://www.newswire.com [Accessed 2006 Apr 29]

    Google Scholar 

  2. American Academy of Neurology. Parkinson disease treatments show risk for developing gambling problems [media release]. 24 Mar 2006. Newswire [online]. Available from URL: http://www.newswire.com [Accessed 2006 Apr 29]

    Google Scholar 

Reference

  • Noyes K, Liu H, Li Y, et al. Economic burden associated with Parkinson’s disease on elderly Medicare beneficiaries. Mov Disord 2006 Mar; 21(3): 362–72

    Article  PubMed  Google Scholar 

Reference

  • Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006 Mar; 21(3): 343–53

    Article  PubMed  Google Scholar 

Reference

  • Roch B, Eckert L, Guelfucci F, et al. A cost-effectiveness comparison of rasagiline with dopamine agonists for delaying levodopa use in early parkinsonian patients in the United Kingdom [abstract no. PNL3]. 2nd Asia-Pacific International Society for Pharmacoeconomics and Outcomes Research Conference; 2006 Mar 5; Shanghai [online]. Available from URL: http://www.ispor.org [Accessed 2006 Apr 29]

Reference

  • Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord 2006 Apr; 21(4): 456–61

    Article  PubMed  Google Scholar 

Reference

  • ACADIA Pharmaceuticals announces positive results from phase II trial of ACP-103 for treatment-induced psychosis in patients with Parkinson’s disease [media release]. 23 Mar 2006. ACADIA Pharmaceuticals Inc. [online]. Available from URL: http://www.acadiapharm.com [Accessed 2006 Apr 1]

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerontology Forum. Drugs Aging 23, 601–615 (2006). https://doi.org/10.2165/00002512-200623070-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200623070-00008

Search

Navigation